Status
Conditions
About
Screening study to determine incidence of MGUS in this patient population
Full description
This study is designed to observe the incidence of monoclonal gammopathy of undetermined significance (MGUS) among obese patients planning to have weight reduction surgery or planning to enter into a physician monitored weight loss program and to follow the regression or progression of MGUS following surgery or the initiation of the weight loss program.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Male or female patients 30 years or older planning to undergo weight reduction surgery or planning to enter into a physician monitored weight loss program
Patients must be obese, defined as a BMI ≥ 30 as calculated by the formula:
weight in pounds / height squared x 703 = BMI
Subject consent and authorization for the release of health information must be obtained according to local institutional guidelines.
To remain in the study for the follow-up phase, the baseline screening test must indicate that a patient has MGUS.
Exclusion criteria
Loading...
Central trial contact
Rafat Abonour, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal